COMP <GO>
ANIK vs INFU // EV/EBITDA & P/E VALUATION
Anika Therapeutics Inc. (NASDAQ) VS. InfuSystems Holdings Inc. (NYSE) • 15-METRIC TALLY: ANIK 2
— INFU 7
■ METRIC PARITY
LAST: $21.79 (+1.11%) • MKT CAP: $291.6M
valuation
—
LAST: $14.45 (+0.91%) • MKT CAP: $287.8M
valuation
24.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIK VS. INFU)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANIK | INFU | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.60% | 56.00% | +0.60 | ANIK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | 12.80% | -23.00 | INFU | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 24.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.50% | 8.29% | -6.79 | INFU | /fcf-yield <GO> |
| Operating Margin | -9.80% | 8.30% | -18.10 | INFU | /operating-margins <GO> |
| Net Profit Margin | -9.80% | 4.60% | -14.40 | INFU | /net-margins <GO> |
| Revenue Growth (YoY) | -5.90% | 6.40% | -12.30 | INFU | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.16 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | INFU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 58.6 | -5.44 | INFU | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 40.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $291.6M | $287.8M | $3.8M | ANIK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANIK REV | INFU REV | ANIK GROSS % | INFU GROSS % | ANIK FCF | INFU FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $112.8M | $143.4M | 56.6% | 56.0% | $4.4M | $23.8M |
| FY 2024 | $119.9M | $134.9M | 63.4% | 52.2% | -$2.3M | $19.4M |
| FY 2023 | $120.8M | $125.8M | — | — | -$1.8M | $11.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIK // BETA —
INFU // BETA —